

The Applicant is providing the Examiner with a copy of the substitute specification presented on a single side of the paper thus, reconsideration is respectfully requested in respect of the objection to the disclosure.

IN THE CLAIMS

Please amend Claim 263 as follows:

*Ex Sub 2*

~~263. (Thrice Amended) A method of preventing a topical infection resulting from a condition or disease in a human involving underperfused tissue and pathological tissue in humans, the method comprising the administration of an effective amount of an anti-metabolite agent and a sufficient amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and its non-toxic salts and combinations thereof to facilitate the transport and penetration of the agent at a site to be treated by the agents passing through the tissue through the cell membranes into the individual cells to be treated wherein the molecular weight of the form of hyaluronic acid is in the range of 150,000 to 750,000 daltons, and said amount of the form of hyaluronic acid is sufficient to provide a dosage greater than 10mg and less than 3000mg.~~

The Examiner has rejected claims 11, 122, 123, 151, 187, 216, 218, and 261-264 under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention namely, the terminology "less than 3000 mg.", the Examiner purports, was not disclosed or suggested by the specification